Chronic IllnessesNCT02870387
Inpatient Consultation for High-Risk Chronically Ill Children Receiving Care in an Enhanced Medical Home
A study testing Comprehensive Care with Inpatient consultation and Usual Inpatient Care in people with Chronic Illnesses, run by The University of Texas Health Science Center, Houston at 1 site in United States.
Trial summary
The investigators will conduct a pilot quality improvement trial to assess the impact of offering inpatient consultation to further optimize coordination and improve care for high-risk chronically ill children receiving comprehensive care in an enhanced medical home. Read more about this study
- Who is it for?
- Ages Up to 18 years
- Conditions the study is for
- Chronic Illnesses
- What is being tested?
- Comprehensive Care with Inpatient consultation and Usual Inpatient Care
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 342 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2016to 26 Jan 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- HRCC patients who require admission to CMHH
Who cannot join
- HRCC patients with a Do-Not-Resuscitate (DNR) order
- HRCC patients with congenital heart disease if repair is needed
- HRCC patients seen solely for compassionate care
- HRCC patients who are ≥ 18 years of age at study initiation
- HRCC patients with active cancer
- HRCC patients with mitochondrial disorders
Trial locations and contacts
1 site in 1 country.
United States1 site
The University of Texas Medical School at Houston
Houston, Texas, 77030
About this study
Official title: Inpatient Consultation for High-Risk Chronically Ill Children Receiving Care in an Enhanced Medical Home: a Pilot Quality Improvement Study
The investigators will conduct a pilot quality improvement trial to assess the impact of offering inpatient consultation to further optimize coordination and improve care for high-risk chronically ill children receiving comprehensive care in an enhanced medical home.
Read the detailed description
Background and Rationale: Comprehensive care (CC) provided in the High-Risk Children's Clinic (HRCC) at The University of Texas Health Science Center at Houston (UTHealth) involves care for acute and chronic conditions from a team of ethnically diverse pediatricians and nurse practitioners who are highly trained and experienced in treating medically complex and fragile children. This clinic serves as a novel medical home where both primary and specialty services are provided in the same place at the same visit. Acute problems presenting before 4 pm are seen the same day or if they occur over the weekend, on Monday morning. All parents have the cell phone number to directly reach 1 of the primary care clinicians at all hours. Multiple measures are used to promote and ensure the highest quality of care such as daily checks of emergency department and hospital logs to ensure prompt follow-up and coordination of care, weekly HRCC provider team meetings to review the care provided before every ED visit and hospitalization, high priority given to minimizing unnecessary ED visits and hospitalizations, and a relatively low patient-to-staff ratio of no greater than 100 (to allow for longer clinic visits, more telephone calls and e-mails, and extensive quality improvement measures).
Comprehensive care undoubtedly increases access to high-quality healthcare for high-risk disadvantaged children. The findings of our previous randomized trial of comprehensive care vs. usual care that were given accelerated publication in JAMA (2014) have attracted national attention as the best evidence to date supporting medical homes to reduce either adverse outcomes or costs (Mosquera et al., 2014). Comprehensive care resulted in major benefits (ED visits, hospital admissions \& days, pediatric ICU admissions \& days were all reduced by 47-69%) and savings of >$10,000/child/year from the health system perspective. Indeed, the improvements in outcomes and reduction in costs exceed those previously reported in prior studies of medical homes for patients of any age or condition (Mosquera et al., 2014; Homer et al., 2008; Jackson et al., 2013).
Despite these demonstrated benefits, high-risk patients seen in the High-Risk Children's Clinic still experience high rates of morbidity and often require hospitalization for treatment of acute exacerbations of their underlying chronic conditions. In 2015, 100 HRCC patients experienced a total of 175 admissions at Children's Memorial Hermann Hospital (CMHH) for a mean length of stay (LOS) of 7.1 days. As a result, a pilot quality improvement (QI) trial will be conducted to assess the impact of offering inpatient consultation (IC) at CMHH to further optimize coordination and integration of inpatient and outpatient care and reduce total hospital days per child-year.
Inclusion/Exclusion criteria: HRCC patients who require admission to CMHH will be included in the pilot trial. HRCC patients ≥ 18 years of age at study initiation will be excluded from the pilot trial and so will those with a Do-Not-Resuscitate (DNR) order, unrepaired congenital heart disease, active cancer, mitochondrial disorder, or seen in the HRCC clinic solely for compassionate care.
Enrollment period: All eligible HRCC patients who are admitted to CMHH between October 3, 2016 and October 2, 2019 will be enrolled in the pilot trial.
Design: All eligible HRCC patients will be randomized prior to study enrollment to either usual inpatient care or comprehensive care with inpatient consultation utilizing a computer-generated algorithm with variable block sizes. Patients will be stratified into two groups according to whether or not they are considered to have greater than median risk of repeated hospitalizations for patients in this study. Baseline hospitalization risk (high-risk or very high-risk) will be determined by the clinic's medical director based on the patient's diagnosis and clinical course.
Treatment Groups:
Usual Inpatient Care: Inpatient care at CMHH will be provided by the hospital inpatient team (residents, fellows, and attending faculty physicians) with usual occasional communication with HRCC providers. This care will not be modified by the study protocol.
Comprehensive care with Inpatient Consultation: Inpatient care at CMHH will include inpatient consultation by HRCC providers with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum. The HRCC providers will review the inpatient care plan and make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. The inpatient consultations will consist of either face-to-face consultations, non-face-to-face consultations, or a phone call to the inpatient physician team.
Data Collection and Management: Research Electronic Data Capture (REDCap) software will be utilized to collect and manage predefined study variable data. REDCap is a secure, web-based application designed to support electronic data capture for research studies providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources.
Cost Assessment: Total hospital costs for CMHH admission and any ER visit or re-admission within 30 days after CMHH discharge will be assessed from a health system perspective by multiplying total hospital charges by department-specific cost-to-charge ratios specified in the hospital's annual Medicare cost report. Hospital costs for the comprehensive care with inpatient consultation group will be augmented by the incremental HRCC personnel cost for providing inpatient consultation based on the HRCC staff salary and fringe data. All costs will be inflated to the year of analysis based on the Consumer Price Index for medical services. The investigators will consider the program to be highly cost-effective if it reduces the total number of hospital days per child-year without increasing costs, reduces costs without increasing the total number of hospital days per child-year, or reduces both.
Statistical and Economic Analyses: All intent-to-treat statistical and economic analyses will be performed using multilevel generalized estimating equations (GEE) models with exchangeable correlation to account for patient and family clustering, robust standard errors, and log link. The economic analyses will be performed according to current standards for such analyses (Drummond et al., 2005; Gold et al., 1996; Siegel et al., 1996; Sanders et al., 2016). Differences in hospital days and costs between treatment groups will be assessed using GEE models with gamma distribution. Rates of secondary outcomes will be assessed using binomial GEE models, whereas total number of secondary outcomes will be assessed with negative binomial GEE models. All the models will be adjusted for the trial's stratifying variable (baseline risk of repeated hospitalization) and for within-family correlation. In this small pilot study, some treatment effects that would be considered important by family members and clinicians (reduced hospital days) may not be statistically significant. As a result, Bayesian analyses will also be performed to estimate the probability of a benefit of a given magnitude and evaluate whether further study is justified. Neutral and skeptical priors will be used. The study will also allow us to obtain the experience and data needed to refine the process for providing inpatient consultations for high-risk chronically ill children. All frequentist statistical analyses will be performed using Stata version 13.1 (Stata Corp, College Station, TX). The Bayesian model will be implemented using OpenBUGS.
Stopping Rules. We plan to enroll patients in the pilot trial for 3 years. However, under predefined stopping rules, enrollment will cease if Bayesian analyses performed at the end of the first year identifies a 97.5% or greater probability that inpatient consultation results in at least a 10% reduction in the total number of hospital days per child-year relative to usual inpatient care or if at the end of the second year it identifies a 95% or greater probability of such a reduction.
- Conditions
- Chronic Illnesses
- Being tested
- Comprehensive Care with Inpatient consultation, Usual Inpatient Care
- Keywords
- chronic illness, children, children with medical complexity, medical home, inpatient consultation
- Medical subject headings
- Chronic Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Comprehensive Care with Inpatient consultationOther
Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
Usual Inpatient CareOther
High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
| Study group | Role | What they receive |
|---|---|---|
| Usual Inpatient Care | Active comparator | Usual Inpatient Care: High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol. Receives: Other: Usual Inpatient Care |
| Comprehensive Care with Inpatient Consultation | Experimental | Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record. Receives: Other: Comprehensive Care with Inpatient consultation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of hospital days per child-year
Total number of hospital days at Children's Memorial Hermann Hospital (CMHH) per child-year
Measured: Within study period
Secondary outcomes (9)
Parent/caregiver satisfaction
Score on pre-selected Hospital CAHPS survey questions administered to parent/caregiver within 10 days after discharge from CMHH
Measured: Within 10 days after discharge from CMHH
Number of parents/caregivers that receive a follow-up phone call from an HRCC provider within 36 hours after discharge from CMHH
Total number of parents/caregivers that receive a follow-up phone call from an HRCC provider within 36 hours after discharge from CMHH
Measured: Within 36 hours of discharge from CMHH
Number of patients that receive a follow-up clinic visit in the HRCC within 10 days after discharge from CMHH.
Total number of patients that receive a follow-up clinic visit in the HRCC within 5-10 days after discharge from CMHH.
Measured: Within 10 days after discharge from CMHH
Number of inpatient consultations with the CMHH inpatient physician team during admissions
Total number of inpatient consultations with the CMHH inpatient physician team during admissions for eligible HRCC patients-ie, face-to-face consultations, non-face-to-face consultations, or phone calls to the inpatient physician team.
Measured: Between CMHH admission and discharge
Number of PICU days
Total number of PICU days per child-year at CMHH
Measured: Within study period
Number of ER visits within 30 days after CMHH discharge
Total number of ER visits within 30 days after CMHH discharge
Measured: Within 30 days after discharge from CMHH
Number of re-admissions within 30 days after CMHH discharge
Total number of re-admissions within 30 days after CMHH discharge
Measured: Within 30 days after discharge from CMHH
Rate of serious illnesses (death, prolonged hospitalization >7 days, or PICU admission)
Rate of children who develop serious illness (death, PICU admission, or prolonged hospitalization >7 days)
Measured: Within study period
Hospital costs for CMHH admission and any ER visit or re-admission within 30 days after CMHH discharge
Total hospital costs assessed by multiplying hospital charges by department-specific cost-to-charge ratios for CMHH admission and any ER visit or re-admission within 30 days after CMHH discharge. Hospital costs for the comprehensive care with inpatient consultation group will be augmented by the incremental HRCC personnel cost for providing inpatient consultation based on the HRCC staff salary and fringe data.
Measured: Within study period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2016 (estimated)
- Study startOct 2016
- Primary completion26 Jan 2018
- Study completion26 Jan 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Chronic IllnessesStudies of the same condition, open and under way.
- More trials run by The University of Texas Health Science Center, HoustonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 342 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ricardo A. Mosquera, The University of Texas Health Science Center, Houston
- Investigators
- Ricardo Mosquera, MD, Principal investigator, The University of Texas Medical School at Houston
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02870387
- Sponsor's protocol ID
- HSC-MS-16-0462
- Other IDs
- 5KL2TR000370-10, 5KL2TR000370
- Status last verified
- Mar 2018
- First submitted
- 5 Aug 2016
- Last updated
- 13 Jul 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mosquera RA, Avritscher EB, Samuels CL, Harris TS, Pedroza C, Evans P, Navarro F, Wootton SH, Pacheco S, Clifton G, Moody S, Franzini L, Zupancic J, Tyson JE. Effect of an enhanced medical home on serious illness and cost of care among high-risk children with chronic illness: a randomized clinical trial. JAMA. 2014 Dec 24-31;312(24):2640-8. doi: 10.1001/jama.2014.16419.
PubMed 25536255Homer CJ, Klatka K, Romm D, Kuhlthau K, Bloom S, Newacheck P, Van Cleave J, Perrin JM. A review of the evidence for the medical home for children with special health care needs. Pediatrics. 2008 Oct;122(4):e922-37. doi: 10.1542/peds.2007-3762.
PubMed 18829788Jackson GL, Powers BJ, Chatterjee R, Bettger JP, Kemper AR, Hasselblad V, Dolor RJ, Irvine RJ, Heidenfelder BL, Kendrick AS, Gray R, Williams JW. The patient centered medical home. A systematic review. Ann Intern Med. 2013 Feb 5;158(3):169-78. doi: 10.7326/0003-4819-158-3-201302050-00579.
PubMed 24779044Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York, NY: Oxford University Press; 2005.
Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press;1996.
Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 Oct 23-30;276(16):1339-41. doi: 10.1001/jama.276.16.1339.
PubMed 8861994Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195.
PubMed 27623463Mosquera RA, Avritscher EBC, Pedroza C, Bell CS, Samuels CL, Harris TS, Eapen JC, Yadav A, Poe M, Parlar-Chun RL, Berry J, Tyson JE. Hospital Consultation From Outpatient Clinicians for Medically Complex Children: A Randomized Clinical Trial. JAMA Pediatr. 2021 Jan 1;175(1):e205026. doi: 10.1001/jamapediatrics.2020.5026. Epub 2021 Jan 4.
PubMed 33252671
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Inpatient Consultation for High-Risk Chronically Ill Children Receiving Care in an Enhanced Medical Home: a Pilot Quality Improvement Study
- ClinicalTrials.gov ID
- NCT02870387
- Acronym / sponsor ID
- HSC-MS-16-0462
- Conditions
- Chronic Illnesses
- Keywords
- chronic illness, children, children with medical complexity, medical home, inpatient consultation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 342 participants (actual)
- Lead sponsor
- The University of Texas Health Science Center, HoustonUniversity, hospital or other
- Study start
- Oct 2016
- Primary completion
- 26 Jan 2018 (actual)
- Study completion
- 26 Jan 2018 (actual)
- First posted
- 17 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators will conduct a pilot quality improvement trial to assess the impact of offering inpatient consultation to further optimize coordination and improve care for high-risk chronically ill children receiving comprehensive care in an enhanced medical home.
Detailed description
Background and Rationale: Comprehensive care (CC) provided in the High-Risk Children's Clinic (HRCC) at The University of Texas Health Science Center at Houston (UTHealth) involves care for acute and chronic conditions from a team of ethnically diverse pediatricians and nurse practitioners who are highly trained and experienced in treating medically complex and fragile children. This clinic serves as a novel medical home where both primary and specialty services are provided in the same place at the same visit. Acute problems presenting before 4 pm are seen the same day or if they occur over the weekend, on Monday morning. All parents have the cell phone number to directly reach 1 of the primary care clinicians at all hours. Multiple measures are used to promote and ensure the highest quality of care such as daily checks of emergency department and hospital logs to ensure prompt follow-up and coordination of care, weekly HRCC provider team meetings to review the care provided before every ED visit and hospitalization, high priority given to minimizing unnecessary ED visits and hospitalizations, and a relatively low patient-to-staff ratio of no greater than 100 (to allow for longer clinic visits, more telephone calls and e-mails, and extensive quality improvement measures).
Comprehensive care undoubtedly increases access to high-quality healthcare for high-risk disadvantaged children. The findings of our previous randomized trial of comprehensive care vs. usual care that were given accelerated publication in JAMA (2014) have attracted national attention as the best evidence to date supporting medical homes to reduce either adverse outcomes or costs (Mosquera et al., 2014). Comprehensive care resulted in major benefits (ED visits, hospital admissions \& days, pediatric ICU admissions \& days were all reduced by 47-69%) and savings of >$10,000/child/year from the health system perspective. Indeed, the improvements in outcomes and reduction in costs exceed those previously reported in prior studies of medical homes for patients of any age or condition (Mosquera et al., 2014; Homer et al., 2008; Jackson et al., 2013).
Despite these demonstrated benefits, high-risk patients seen in the High-Risk Children's Clinic still experience high rates of morbidity and often require hospitalization for treatment of acute exacerbations of their underlying chronic conditions. In 2015, 100 HRCC patients experienced a total of 175 admissions at Children's Memorial Hermann Hospital (CMHH) for a mean length of stay (LOS) of 7.1 days. As a result, a pilot quality improvement (QI) trial will be conducted to assess the impact of offering inpatient consultation (IC) at CMHH to further optimize coordination and integration of inpatient and outpatient care and reduce total hospital days per child-year.
Inclusion/Exclusion criteria: HRCC patients who require admission to CMHH will be included in the pilot trial. HRCC patients ≥ 18 years of age at study initiation will be excluded from the pilot trial and so will those with a Do-Not-Resuscitate (DNR) order, unrepaired congenital heart disease, active cancer, mitochondrial disorder, or seen in the HRCC clinic solely for compassionate care.
Enrollment period: All eligible HRCC patients who are admitted to CMHH between October 3, 2016 and October 2, 2019 will be enrolled in the pilot trial.
Design: All eligible HRCC patients will be randomized prior to study enrollment to either usual inpatient care or comprehensive care with inpatient consultation utilizing a computer-generated algorithm with variable block sizes. Patients will be stratified into two groups according to whether or not they are considered to have greater than median risk of repeated hospitalizations for patients in this study. Baseline hospitalization risk (high-risk or very high-risk) will be determined by the clinic's medical director based on the patient's diagnosis and clinical course.
Treatment Groups:
Usual Inpatient Care: Inpatient care at CMHH will be provided by the hospital inpatient team (residents, fellows, and attending faculty physicians) with usual occasional communication with HRCC providers. This care will not be modified by the study protocol.
Comprehensive care with Inpatient Consultation: Inpatient care at CMHH will include inpatient consultation by HRCC providers with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum. The HRCC providers will review the inpatient care plan and make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. The inpatient consultations will consist of either face-to-face consultations, non-face-to-face consultations, or a phone call to the inpatient physician team.
Data Collection and Management: Research Electronic Data Capture (REDCap) software will be utilized to collect and manage predefined study variable data. REDCap is a secure, web-based application designed to support electronic data capture for research studies providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources.
Cost Assessment: Total hospital costs for CMHH admission and any ER visit or re-admission within 30 days after CMHH discharge will be assessed from a health system perspective by multiplying total hospital charges by department-specific cost-to-charge ratios specified in the hospital's annual Medicare cost report. Hospital costs for the comprehensive care with inpatient consultation group will be augmented by the incremental HRCC personnel cost for providing inpatient consultation based on the HRCC staff salary and fringe data. All costs will be inflated to the year of analysis based on the Consumer Price Index for medical services. The investigators will consider the program to be highly cost-effective if it reduces the total number of hospital days per child-year without increasing costs, reduces costs without increasing the total number of hospital days per child-year, or reduces both.
Statistical and Economic Analyses: All intent-to-treat statistical and economic analyses will be performed using multilevel generalized estimating equations (GEE) models with exchangeable correlation to account for patient and family clustering, robust standard errors, and log link. The economic analyses will be performed according to current standards for such analyses (Drummond et al., 2005; Gold et al., 1996; Siegel et al., 1996; Sanders et al., 2016). Differences in hospital days and costs between treatment groups will be assessed using GEE models with gamma distribution. Rates of secondary outcomes will be assessed using binomial GEE models, whereas total number of secondary outcomes will be assessed with negative binomial GEE models. All the models will be adjusted for the trial's stratifying variable (baseline risk of repeated hospitalization) and for within-family correlation. In this small pilot study, some treatment effects that would be considered important by family members and clinicians (reduced hospital days) may not be statistically significant. As a result, Bayesian analyses will also be performed to estimate the probability of a benefit of a given magnitude and evaluate whether further study is justified. Neutral and skeptical priors will be used. The study will also allow us to obtain the experience and data needed to refine the process for providing inpatient consultations for high-risk chronically ill children. All frequentist statistical analyses will be performed using Stata version 13.1 (Stata Corp, College Station, TX). The Bayesian model will be implemented using OpenBUGS.
Stopping Rules. We plan to enroll patients in the pilot trial for 3 years. However, under predefined stopping rules, enrollment will cease if Bayesian analyses performed at the end of the first year identifies a 97.5% or greater probability that inpatient consultation results in at least a 10% reduction in the total number of hospital days per child-year relative to usual inpatient care or if at the end of the second year it identifies a 95% or greater probability of such a reduction.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Usual Inpatient Care | Active comparator | Other: Usual Inpatient CareUsual Inpatient Care: High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol. |
| Comprehensive Care with Inpatient Consultation | Experimental | Other: Comprehensive Care with Inpatient consultationComprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record. |
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- HRCC patients who require admission to CMHH
Key exclusion criteria (6 listed)
- HRCC patients with a Do-Not-Resuscitate (DNR) order
- HRCC patients with congenital heart disease if repair is needed
- HRCC patients seen solely for compassionate care
- HRCC patients who are ≥ 18 years of age at study initiation
- HRCC patients with active cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Comprehensive Care with Inpatient consultationComprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record. | Other | Comprehensive Care with Inpatient Consultation |
| Usual Inpatient CareHigh-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol. | Other | Usual Inpatient Care |
Primary outcome
Number of hospital days per child-year
Time frame: Within study period
Total number of hospital days at Children's Memorial Hermann Hospital (CMHH) per child-year
9 secondary outcomes
Parent/caregiver satisfaction
Time frame: Within 10 days after discharge from CMHH
Number of parents/caregivers that receive a follow-up phone call from an HRCC provider within 36 hours after discharge from CMHH
Time frame: Within 36 hours of discharge from CMHH
Number of patients that receive a follow-up clinic visit in the HRCC within 10 days after discharge from CMHH.
Time frame: Within 10 days after discharge from CMHH
Number of inpatient consultations with the CMHH inpatient physician team during admissions
Time frame: Between CMHH admission and discharge
Number of PICU days
Time frame: Within study period
Number of ER visits within 30 days after CMHH discharge
Time frame: Within 30 days after discharge from CMHH
Number of re-admissions within 30 days after CMHH discharge
Time frame: Within 30 days after discharge from CMHH
Rate of serious illnesses (death, prolonged hospitalization >7 days, or PICU admission)
Time frame: Within study period
Hospital costs for CMHH admission and any ER visit or re-admission within 30 days after CMHH discharge
Time frame: Within study period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2018.
- Background: PubMed 25536255Mosquera RA, Avritscher EB, Samuels CL, Harris TS, Pedroza C, Evans P, Navarro F, Wootton SH, Pacheco S, Clifton G, Moody S, Franzini L, Zupancic J, Tyson JE. Effect of an enhanced medical home on serious illness and cost of care among high-risk children with chronic illness: a randomized clinical trial. JAMA. 2014 Dec 24-31;312(24):2640-8. doi: 10.1001/jama.2014.16419.
- Background: PubMed 18829788Homer CJ, Klatka K, Romm D, Kuhlthau K, Bloom S, Newacheck P, Van Cleave J, Perrin JM. A review of the evidence for the medical home for children with special health care needs. Pediatrics. 2008 Oct;122(4):e922-37. doi: 10.1542/peds.2007-3762.
- Background: PubMed 24779044Jackson GL, Powers BJ, Chatterjee R, Bettger JP, Kemper AR, Hasselblad V, Dolor RJ, Irvine RJ, Heidenfelder BL, Kendrick AS, Gray R, Williams JW. The patient centered medical home. A systematic review. Ann Intern Med. 2013 Feb 5;158(3):169-78. doi: 10.7326/0003-4819-158-3-201302050-00579.
- BackgroundDrummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York, NY: Oxford University Press; 2005.
- BackgroundGold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press;1996.
- Background: PubMed 8861994Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 Oct 23-30;276(16):1339-41. doi: 10.1001/jama.276.16.1339.
- Background: PubMed 27623463Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195.
- Derived from this study: PubMed 33252671Mosquera RA, Avritscher EBC, Pedroza C, Bell CS, Samuels CL, Harris TS, Eapen JC, Yadav A, Poe M, Parlar-Chun RL, Berry J, Tyson JE. Hospital Consultation From Outpatient Clinicians for Medically Complex Children: A Randomized Clinical Trial. JAMA Pediatr. 2021 Jan 1;175(1):e205026. doi: 10.1001/jamapediatrics.2020.5026. Epub 2021 Jan 4.
- Individual participant dataSharing planned: No
Related trials for Chronic Illnesses
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ricardo Mosquera, MD principal investigator
The University of Texas Medical School at Houston
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Comprehensive Care with Inpatient consultation and Usual Inpatient Care in people with Chronic Illnesses, run by The University of Texas Health Science Center, Houston at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jul 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of hospital days per child-year (time frame: Within study period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02870387, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2018.